iShares Biotechnology ETF (IBB) Stock Price & Analysis
iShares Biotechnology ETF (IBB) is trading at USD 212.51, up 0.95% today, as of October 21, 2026 at 18:42 UTC (US market open; quotes may be delayed), according to Nexqual market data.
IBB last closed at USD 210.5; today's session has ranged USD 210.18–213.3 on volume of 934,150 shares. Market capitalization is —, with a 52-week range of USD 153.25–217.12 (NGM). Source: Nexqual, retrieved October 21, 2026 at 18:42 UTC.
Also available as compact Markdown for AI agents: nexqual.com/IBB.md
Key facts (IBB)
- Total return with dividends: 1Y +36.5% vs S&P 500 +16.6%; 5Y +35.8% vs S&P 500 +82.7%.
Total return (dividends reinvested) (IBB)
| 1Y (from 2025-10-21) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +36.5% | +35.8% |
| S&P 500 (SPY) | +16.6% | +82.7% |
| Per year | +36.5% | +6.3% |
| Volatility (annualized) | 22.6% | 21.6% |
| Max drawdown | -9.6% (Jan 2026→Mar 2026) | -31.3% (Oct 2021→Jun 2022) |
IBB options: expected move
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 30 | 24.7% | ±5.7% |
| Dec 18, 2026 | 58 | 25.9% | ±8.3% |
| Jan 15, 2027 | 86 | 24.9% | ±9.7% |
| Mar 19, 2027 | 149 | 23.6% | ±12.1% |
| May 21, 2027 | 212 | 25.6% | ±15.5% |
| Jun 17, 2027 | 239 | 26.2% | ±16.9% |
| Aug 20, 2027 | 303 | 24.8% | ±18.0% |
| Sep 17, 2027 | 331 | 25.7% | ±19.5% |
30-day implied volatility 24.9% vs 25.5% realized over the last 30 trading days. Put/call ratio (volume) 2.36. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 21, 2026 at 18:42 UTC)
| Price | USD 212.51 |
|---|---|
| Change | ▲ 0.95% (up) |
| Previous Close | USD 210.5 |
| Open | USD 210.51 |
| Day Range | USD 210.18 – 213.3 |
| 52-Week Range | USD 153.25 – 217.12 |
| Volume | 934,150 shares |
| Market Cap | — |
| Exchange | NGM |
Technical Analysis (IBB)
Nexqual's technical model rates IBB "BUY" based on 5 bullish and 1 bearish signals across 128 daily candles, as of October 21, 2026 at 18:42 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 55.77 (neutral) |
| vs SMA50 | Above (USD 207.27) |
| MACD | 0.4 (positive) |
Financial Health Score (IBB)
Nexqual rates iShares Biotechnology ETF's overall financial health "Mixed" across five dimensions, as of October 21, 2026 at 18:42 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Mixed — No data |
| Balance Sheet | Mixed — No data |
| Cash Flow | Mixed — No data |
| Efficiency | Mixed — No data |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| XBI | State Street SPDR S&P Biotech E | USD 153.61 | ▲ 0.24% |
| XLV | State Street Health Care Select | USD 178.88 | ▼ 0.53% |
| XLF | State Street Financial Select S | USD 56.08 | ▲ 0.64% |
| XLE | State Street Energy Select Sect | USD 68.06 | ▲ 0.13% |
| XLK | State Street Technology Select | USD 188.81 | ▲ 1.82% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 21, 2026 at 18:42 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt